UniProt P41240 · PDB · AlphaFold · Substrate: pEY · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 99.5% | 0.5% | 87.22 | 0.555 |
| 2 | Ibrutinib | 99.3% | 0.7% | 94.74 | 0.723 |
| 3 | Dasatinib | 98.5% | 1.5% | 87.97 | 0.699 |
| 4 | Ponatinib | 98.4% | 1.6% | 78.23 | 0.534 |
| 5 | Dabrafenib | 92.7% | 7.3% | 94.74 | 0.633 |
| 6 | Ripretinib | 79.3% | 20.6% | 92.95 | 0.674 |
| 7 | Neratinib | 77.1% | 22.9% | 93.18 | 0.597 |
| 8 | Erdafitinib | 73.6% | 26.4% | 95.71 | 0.737 |
| 9 | Repotrectinib | 67.2% | 32.8% | 84.21 | 0.608 |
| 10 | Vandetanib | 66.0% | 34.0% | 95.74 | 0.723 |
| 11 | Nilotinib | 66.0% | 34.0% | 96.49 | 0.765 |
| 12 | Zanubrutinib | 64.0% | 36.0% | 98.24 | 0.788 |
| 13 | Tivozanib | 61.9% | 38.1% | 92.42 | 0.673 |
| 14 | Vemurafenib | 59.1% | 40.9% | 96.49 | 0.598 |
| 15 | Pirtobrutinib | 56.0% | 44.0% | 99.49 | 0.656 |
| 16 | Fostamatinib | 53.0% | 47.0% | 96.74 | 0.613 |
| 17 | Nintedanib | 52.4% | 47.6% | 90.23 | 0.608 |
| 18 | Canertinib | 42.0% | 58.0% | 96.49 | 0.671 |
| 19 | Gilteritinib | 37.0% | 63.0% | 88.97 | 0.506 |
| 20 | Dacomitinib | 36.8% | 63.2% | 97.99 | 0.664 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.20
- Epithelial log2(TPM+1): 5.34
- Fold change: -0.13
- Status: No significant change
Selectivity landscape vs inhibition on CSK
Each point is one of the 92 approved drugs; color = inhibition % on CSK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…